OncoMatch/Clinical Trials/NCT06519591
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
Is NCT06519591 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cadonilimab, LM-302, S-1, paclitaxel for gastric cancer stage iv.
Treatment: Cadonilimab, LM-302, S-1, paclitaxel — In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Required: CLDN18 overexpression (≥ 25%, and the proportion of positive cells greater than 50% of the cases accounted for not less than 70%)
Claudin 18.2 positive (≥ 25%, and the proportion of positive cells greater than 50% of the cases accounted for not less than 70%)
Required: HER2 (ERBB2) wild-type
her 2 (-)
Disease stage
Required: Stage IV
Metastatic disease required
Peritoneal metastases from gastric cancer requiring definitive diagnosis by laparoscopy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy (PD-1, PD-L1, CTLA-4)
Previously received immunotherapy such as PD-1/PD-L1 and CTLA-4
Cannot have received: targeted therapy (Claudin 18.2)
targeted therapy such as Claudin 18.2
Lab requirements
Blood counts
Adequate bone marrow function required
Kidney function
Moderate or severe renal damage [creatinine clearance ≤ 50 ml/min], or serum creatinine > upper limit of normal (ULN), 115 μmol/L [excluded]
Liver function
Adequate liver function required
Cardiac function
Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, NYHA class II or more severe congestive heart failure or arrhythmia requiring drug intervention, or a history of myocardial infarction in the last 12 months [excluded]
Adequate bone marrow, liver, and renal functions. Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, NYHA class II or more severe congestive heart failure or arrhythmia requiring drug intervention, or a history of myocardial infarction in the last 12 months [excluded]. Moderate or severe renal damage [creatinine clearance ≤ 50 ml/min], or serum creatinine > upper limit of normal (ULN), 115 μmol/L [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify